{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:46:17Z","timestamp":1794624377530,"version":"4.9.1"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamadermatol.2019.3617","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T11:31:17Z","timestamp":1577359877000},"page":"131","source":"Crossref","is-referenced-by-count":210,"title":["Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis"],"prefix":"10.1001","volume":"156","author":[{"given":"Margitta","family":"Worm","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie, Universit\u00e4tsklinikum, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Tokyo Women's Medical University, School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Hospital Universitario Germans Trias i Pujol, Universidad Aut\u00f3noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology, Guys and St Thomas\u2019 Foundation Trust, King\u2019s College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chen","family":"Chan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hultsch","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Staudinger","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Eckert","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Rajadhyaksha","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Stahl","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi190062r1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10023","key":"doi190062r2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis.","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"doi190062r3","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis.","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"doi190062r4","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"doi190062r5","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10039","key":"doi190062r8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u00df2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"doi190062r9","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"doi190062r10","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma.","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"doi190062r11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"doi190062r12","article-title":"Dupilumab efficacy in adults with active eosinophilic esophagitis: a randomized, placebo-controlled phase 2 trial.","author":"Hirano","journal-title":"Gastroenterology"},{"issue":"5","key":"doi190062r13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases.","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"24","key":"doi190062r14","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"doi190062r15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"10013","key":"doi190062r16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"doi190062r17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190062r18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjd.15905","article-title":"Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.","volume":"178","author":"Tsianakas","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi190062r19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"De Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10086","key":"doi190062r20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"doi190062r21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033486","article-title":"Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.","volume":"7","author":"Brezinski","year":"2012","journal-title":"PloS One"},{"issue":"10","key":"doi190062r22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","article-title":"Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.","volume":"9","author":"Hsu","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"doi190062r23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"20","key":"doi190062r24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"doi190062r25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/psp4.12136","article-title":"Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Ra, in atopic dermatitis patients and normal volunteers.","volume":"5","author":"Kovalenko","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"doi190062r26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bjo.82.1.82","article-title":"Systemic and local immunological features of atopic dermatitis patients with ocular complications.","volume":"82","author":"Uchio","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"doi190062r27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis.","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190062r28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.v181.3","article-title":"Conjunctivitis in dupilumab clinical trials.","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190062r29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis.","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"doi190062r30","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.","volume":"30","author":"D\u00e1vila-Seijo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi190062r31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The atopic march and atopic multimorbidity: Many trajectories, many pathways.","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi190062r32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/all.2011.67.issue-1","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference.","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"doi190062r6","year":"2019"},{"key":"doi190062r7","unstructured":"Dupilumab: Summary of Product Characteristics. European Medicines Agency. Published 2017. https:\/\/www.ema.europa.eu\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed August 8, 2019."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2757721\/jamadermatology_worm_2019_oi_190062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:12:06Z","timestamp":1695539526000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2757721"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}